Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00WLO
|
||||
Former ID |
DNC004324
|
||||
Drug Name |
GBR-12909
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Phase 1 | [521723] | ||
Structure |
Download2D MOL |
||||
Formula |
C28H34Cl2F2N2O
|
||||
Canonical SMILES |
C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C<br />4)F.Cl.Cl
|
||||
InChI |
1S/C28H32F2N2O.2ClH/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23;;/h1-3,5-6,8-15,28H,4,7,16-22H2;2*1H
|
||||
InChIKey |
MIBSKSYCRFWIRU-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Adenosine A3 receptor | Target Info | Inhibitor | [527823] | |
Mu-type opioid receptor | Target Info | Inhibitor | [526156] | ||
NetPath Pathway | TCR Signaling Pathway | ||||
Pathway Interaction Database | IL4-mediated signaling events | ||||
References | |||||
Ref 526156 | J Med Chem. 2001 Oct 11;44(21):3391-401.From hit to lead. Analyzing structure-profile relationships. | ||||
Ref 527823 | J Med Chem. 2005 Nov 3;48(22):6887-96.2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.